Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease
Globe Newswire•12/10/2026•07:00 ET
0
Key Highlights
- ➤12-month flare-free probability reached 0.93 with adjudicated rescue-therapy flares
- ➤Obexelimab cut cumulative glucocorticoid toxicity versus placebo at week 52
- ➤Vaccine responses reached 86% for influenza and 100% for COVID-19
- ➤No disease flares occurred during the 34.6-day treatment-free vaccination window
- ➤Zenas expects Phase 2 SunStone SLE topline results in 4Q 2026
Expert Statements
Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma
“IgG4-RD is a chronic disease that may require ongoing management, even after an acute flare is controlled”
Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma
“Together, these new findings reinforce the potential role of obexelimab in long-term disease management, including helping patients remain flare-free, reducing steroid exposure, and potentially supporting vaccine responses following a treatment-free window.”
– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab –
– Additional analyses of secondary endpoints showed that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity at week 52 –
Get started
Create a free account to read the full story.